{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:03:33Z","timestamp":1792015413963,"version":"4.4.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Women and Children\u2019s Health Research Institute"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 142202"],"award-info":[{"award-number":["MOP 142202"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hair Massacure Foundation"},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation","doi-asserted-by":"crossref","award":["RES0048095"],"award-info":[{"award-number":["RES0048095"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Edmonton Civic Employees Charitable Assistance Fund"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Overexpression and persistent activation of STAT5 play an important role in the development and progression of acute lymphoblastic leukemia (ALL), the most common pediatric cancer. Small interfering RNA (siRNA)-mediated downregulation of STAT5 represents a promising therapeutic approach for ALL to overcome the limitations of current treatment modalities such as high relapse rates and poor prognosis. However, to effectively transport siRNA molecules to target cells, development of potent carriers is of utmost importance to surpass hurdles of delivery. In this study, we investigated the use of lipopolymers as non-viral delivery systems derived from low molecular weight polyethylenimines (PEI) substituted with lauric acid (Lau), linoleic acid (LA) and stearic acid (StA) to deliver siRNA molecules to ALL cell lines and primary samples. Among the lipid-substituted polymers explored, Lau- and LA-substituted PEI displayed excellent siRNA delivery to SUP-B15 and RS4;11 cells. STAT5A gene expression was downregulated (36\u201392%) in SUP-B15 and (32%) in RS4;11 cells using the polymeric delivery systems, which consequently reduced cell growth and inhibited the formation of colonies in ALL cells. With regard to ALL primary cells, siRNA-mediated STAT5A gene silencing was observed in four of eight patient cells using our leading polymeric delivery system, 1.2PEI-Lau8, accompanied by the significant reduction in colony formation in three of eight patients. In both BCR-ABL positive and negative groups, three of five patients demonstrated marked cell growth inhibition in both MTT and trypan blue exclusion assays using 1.2PEI-Lau8\/siRNA complexes in comparison with their control siRNA groups. Three patient samples did not show any positive results with our delivery systems. Differential therapeutic responses to siRNA therapy observed in different patients could result from variable genetic profiles and patient-to-patient variability in delivery. This study supports the potential of siRNA therapy and the designed lipopolymers as a delivery system in ALL therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0251719","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T20:02:32Z","timestamp":1624392152000},"page":"e0251719","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)"],"prefix":"10.1371","volume":"16","author":[{"given":"Mahsa","family":"Mohseni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remant Bahadur","family":"K. C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1346-355X","authenticated-orcid":true,"given":"Mohammad","family":"Nasrullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-4170","authenticated-orcid":true,"given":"Hasan","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"pone.0251719.ref001","doi-asserted-by":"crossref","first-page":"E199","DOI":"10.1503\/cmaj.191292","article-title":"Projected estimates of cancer in Canada in 2020","volume":"192","author":"DR Brenner","year":"2020","journal-title":"CMAJ"},{"key":"pone.0251719.ref002","first-page":"29","article-title":"Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications.","volume":"8","author":"M Mohseni","year":"2018","journal-title":"Am J Blood Res"},{"key":"pone.0251719.ref003","article-title":"Targeting STAT5 or STAT5-regulated pathways suppresses leukemogenesis of Ph+ acute lymphoblastic leukemia","author":"V Minieri","year":"2018","journal-title":"Cancer Res"},{"key":"pone.0251719.ref004","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5858\/arpa.2019-0194-RA","article-title":"BCR-ABL1\u2013like B-acute lymphoblastic leukemia\/lymphoma: A comprehensive review","volume":"144","author":"S Jain","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"pone.0251719.ref005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.beha.2017.07.003","article-title":"The biology of Philadelphia chromosome-like ALL","volume":"30","author":"KG Roberts","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"pone.0251719.ref006","article-title":"Why and how to treat Ph-like ALL?","author":"KG Roberts","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"pone.0251719.ref007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11899-017-0380-3","article-title":"New Therapeutic Strategies in Acute Lymphocytic Leukemia","volume":"12","author":"LM Man","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"pone.0251719.ref008","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/14656566.2017.1340938","article-title":"Novel therapy for childhood acute lymphoblastic leukemia","volume":"18","author":"R Santiago","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"pone.0251719.ref009","article-title":"The STATs of cancer\u2014new molecular targets come of age","author":"H Yu","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"pone.0251719.ref010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2174\/156800906779010227","article-title":"The JAK-STAT pathway: a therapeutic target in hematological malignancies","volume":"6","author":"A Ferrajoli","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"pone.0251719.ref011","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coi.2010.02.004","article-title":"STAT5 in B cell development and leukemia","volume":"22","author":"S Malin","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"pone.0251719.ref012","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4049\/jimmunol.179.2.1068","article-title":"Stat5 Is Essential for Early B Cell Development but Not for B Cell Maturation and Function","volume":"179","author":"X Dai","year":"2007","journal-title":"J Immunol"},{"key":"pone.0251719.ref013","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.4049\/jimmunol.172.8.4770","article-title":"STAT5 Activation Underlies IL7 Receptor-Dependent B Cell Development","volume":"172","author":"CA Goetz","year":"2004","journal-title":"J Immunol"},{"key":"pone.0251719.ref014","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia","volume":"22","author":"KG Roberts","year":"2012","journal-title":"Cancer Cell"},{"key":"pone.0251719.ref015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1097-2765(00)00067-8","article-title":"Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL\/JAK2","volume":"6","author":"J Schwaller","year":"2000","journal-title":"Mol Cell"},{"key":"pone.0251719.ref016","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","article-title":"Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation","volume":"20","author":"S Xie","year":"2001","journal-title":"Oncogene"},{"key":"pone.0251719.ref017","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of Bcr\/Abl-positive leukaemia","volume":"2","author":"A Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"pone.0251719.ref018","first-page":"3421","volume":"117","author":"E a Nelson","year":"2011","journal-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors"},{"key":"pone.0251719.ref019","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"W Warsch","year":"2011","journal-title":"Blood"},{"key":"pone.0251719.ref020","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2014-06-580480","article-title":"Efficacy of JAK\/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia","volume":"125","author":"SL Maude","year":"2015","journal-title":"Blood"},{"key":"pone.0251719.ref021","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K \/ mTOR pathway signaling occurs in human CRLF2 -rearranged B-precursor acute lymphoblastic leukemia","volume":"2","author":"SK Tasian","year":"2012","journal-title":"Blood"},{"key":"pone.0251719.ref022","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.drudis.2016.04.018","article-title":"Current attempts to implement siRNA-based RNAi in leukemia models","volume":"21","author":"H Uluda\u011f","year":"2016","journal-title":"Drug Discov Today"},{"key":"pone.0251719.ref023","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1007\/s11095-015-1741-z","article-title":"Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy","volume":"32","author":"H Montazeri Aliabadi","year":"2015","journal-title":"Pharm Res"},{"key":"pone.0251719.ref024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/med.20244","article-title":"Recent attempts at RNAi-mediated P-glycoprotein downregulation for reversal of multidrug resistance in cancer","volume":"33","author":"M Abbasi","year":"2013","journal-title":"Med Res Rev"},{"key":"pone.0251719.ref025","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","author":"H Gul-Uluda\u011f","year":"2014","journal-title":"Leuk Res"},{"key":"pone.0251719.ref026","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","author":"J Valencia-Serna","year":"2013","journal-title":"J Control Release"},{"key":"pone.0251719.ref027","author":"J Valencia-Serna","year":"2014","journal-title":"Potential of siRNA Therapy in Chronic Myeloid Leukemia"},{"key":"pone.0251719.ref028","article-title":"Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers","author":"HM Aliabadi","year":"2011","journal-title":"Macromol Biosci"},{"key":"pone.0251719.ref029","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","author":"B Landry","year":"2016","journal-title":"J Control Release"},{"key":"pone.0251719.ref030","article-title":"Lipid substitution on low molecular weight (0.6\u20132.0 kDa) polyethylenimine leads to a higher zeta potential of plasmid DNA and enhances transgene expression","author":"KC Remant Bahadur","year":"2011","journal-title":"Acta Biomater"},{"key":"pone.0251719.ref031","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","author":"T Golan","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0251719.ref032","article-title":"Therapeutic RNA aptamers in clinical trials","author":"P Sundaram","year":"2013","journal-title":"Eur J Pharm Sci"},{"key":"pone.0251719.ref033","article-title":"RNA interference in the clinic: Challenges and future directions","author":"V Pecot C","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"pone.0251719.ref034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jconrel.2017.07.002","article-title":"RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients","volume":"261","author":"I Kolosenko","year":"2017","journal-title":"J Control Release"},{"key":"pone.0251719.ref035","article-title":"Identification and targeting of CD22\u0394E12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas","author":"FM Uckun","year":"2018","journal-title":"Cancer Drug Resist"},{"key":"pone.0251719.ref036","author":"DK Edwards","journal-title":"RNAi screening of the tyrosine kinome in primary patient samples of acute myeloid leukemia n.d"},{"key":"pone.0251719.ref037","article-title":"Polymeric Delivery of siRNA against Integrin-\u03b21 (CD29) to Reduce Attachment and Migration of Breast Cancer Cells","author":"DN Meenakshi Sundaram","year":"2017","journal-title":"Macromol Biosci"},{"key":"pone.0251719.ref038","article-title":"Effective Non-Viral Delivery of siRNA to Acute Myeloid Leukemia Cells with Lipid-Substituted Polyethylenimines","author":"B Landry","year":"2012","journal-title":"PLoS One"},{"key":"pone.0251719.ref039","article-title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","author":"J Valencia-Serna","year":"2019","journal-title":"J Control Release"},{"key":"pone.0251719.ref040","article-title":"Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells","author":"MB Parmar","year":"2016","journal-title":"J Biomed Mater Res\u2014Part A"},{"key":"pone.0251719.ref041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/B978-0-08-100520-0.00002-3","article-title":"PEI and its derivatives for gene therapy","author":"KCR Bahadur","year":"2016","journal-title":"Polym Nanomater Gene Ther"},{"key":"pone.0251719.ref042","article-title":"Knocking down barriers: Advances in siRNA delivery.","author":"KA Whitehead","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"pone.0251719.ref043","article-title":"A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine","author":"CY Ming Hsu","year":"2012","journal-title":"Nat Protoc"},{"key":"pone.0251719.ref044","article-title":"SiRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers.","author":"B \u015eahin","year":"2014","journal-title":"Biomaterials"},{"key":"pone.0251719.ref045","article-title":"BCR-Abl silencing by siRNA: A potent approach to sensitize chronic myeloid leukemia cells to tyrosine kinase inhibitor therapy","author":"R Kc","year":"2019","journal-title":"Stem Cells Dev"},{"key":"pone.0251719.ref046","doi-asserted-by":"crossref","first-page":"18341","DOI":"10.18632\/oncotarget.24836","article-title":"Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway","volume":"9","author":"PT Kamga","year":"2018","journal-title":"Oncotarget"},{"key":"pone.0251719.ref047","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-020-2770-9","article-title":"Enabling Combinatorial siRNA Delivery against Apoptosis-Related Proteins with Linoleic Acid and \u03b1-Linoleic Acid Substituted Low Molecular Weight Polyethylenimines","volume":"37","author":"S Plianwong","year":"2020","journal-title":"Pharm Res"},{"key":"pone.0251719.ref048","article-title":"Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability","author":"W He","year":"2014","journal-title":"Mol Ther"},{"key":"pone.0251719.ref049","article-title":"Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: The key role of the STAT5 signal transduction pathway","author":"Q Yao","year":"2005","journal-title":"Leukemia"},{"key":"pone.0251719.ref050","article-title":"Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acutelymphoblastic leukemia","author":"LM Heltemes-Harris","year":"2011","journal-title":"J Exp Med"},{"key":"pone.0251719.ref051","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/nat.2013.0466","article-title":"Target gene abundance contributes to the efficiency of siRNA-mediated gene silencing","volume":"24","author":"SW Hong","year":"2014","journal-title":"Nucleic Acid Ther"},{"key":"pone.0251719.ref052","article-title":"Stat5 is indispensable for the maintenance of Bcr\/Abl-positive leukaemia","author":"A Hoelbl","year":"2010","journal-title":"EMBO Mol Med"},{"key":"pone.0251719.ref053","article-title":"FLT3 activation cooperates with MLL-AF4 fusion protein to abrogate the hematopoietic specification of human ESCs","author":"C Bueno","year":"2013","journal-title":"Blood"},{"key":"pone.0251719.ref054","article-title":"Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene\/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression","author":"H Yamaguchi","year":"2009","journal-title":"Exp Hematol"},{"key":"pone.0251719.ref055","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","article-title":"Pharmacologic inhibition of STAT5 in acute myeloid leukemia","volume":"32","author":"B Wingelhofer","year":"2018","journal-title":"Leukemia"},{"key":"pone.0251719.ref056","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1093\/nar\/gkr065","article-title":"Measurable impact of RNA quality on gene expression results from quantitative PCR","volume":"39","author":"J Vermeulen","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"pone.0251719.ref057","author":"J Forsell","journal-title":"Evaluation of factors affecting real-time PCR performance for diagnosis of Entamoeba histolytica and Entamoeba dispar in clinical stool samples n.d"},{"key":"pone.0251719.ref058","volume-title":"Genotoxicity\u2014A Predict","author":"\u00d6S Aslant\u00fcrk","year":"2018"},{"key":"pone.0251719.ref059","article-title":"Heterogeneity in mechanisms of emergent resistance in pediatric T-cell acute lymphoblastic leukemia **","volume":"7","author":"BD Yadav","journal-title":"Denotes Equal Senior Authorship"},{"key":"pone.0251719.ref060","author":"B Anchang","year":"2018","journal-title":"DRUG-NEM: Optimizing drug combinations using single-cell perturbation response to account for intratumoral heterogeneity"},{"key":"pone.0251719.ref061","author":"H-F Li","year":"2016","journal-title":"Development-associated immunophenotypes reveal the heterogeneous and individualized early responses of adult B-acute lymphoblastic leukemia"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T20:03:07Z","timestamp":1624392187000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0251719"}},"subtitle":[],"editor":[{"given":"Obul Reddy","family":"Bandapalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0251719","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]}}}